Cangene

Cangene is a fully integrated developer and manufacturer of immunotherapies. The company's first drug, WinRho®SDF, has been commercially available since 1980, and since then, the company has established a solid track record in the development and commercialization of plasma-derived products that address multiple therapeutic areas. Its current product portfolio includes purified concentrated antibody preparations (hyperimmune) targeted for use in infectious diseases, hematology, transplantation, and biodefense. Four of the company’s hyperimmune products are approved in the United States and/or Canada, with three products included in the U.S. Strategic National Stockpile.